Topical methylene blue nanoformulation for the photodynamic therapy of acne vulgaris

Arch Dermatol Res. 2023 May;315(4):885-893. doi: 10.1007/s00403-022-02464-7. Epub 2022 Nov 14.

Abstract

Acne vulgaris is a common skin disease caused by multifactorial reasons involving excessive sebum secretion and inflammation by Cutibacterium acnes (C. acnes). Various conventional therapies are available for the treatment of acne vulgaris; however, topical photodynamic therapy (PDT) has attracted much attention because of its great potential for sebum-reducing, anti-inflammatory, and antimicrobial activities. Although 5-aminolevulinic acid (ALA) has been broadly used as a photosensitizer for topical PDT, it has several limitations such as long incubation time, pain, and post-inflammatory hyperpigmentation. Here, we report a biocompatible nanoformulation consisting of methylene blue and salicylic acid (MBSD), as a potent PDT and acne therapeutics, enclosed within oleic acid. Photoactivated MBSD showed antimicrobial activity against C. acnes along with long-term stability. When 24 patients with acne were treated with MBSD and light irradiation 5 times at 1-week intervals, MBSD-based PDT exhibited a remarkable reduction in acne lesions and sebum production. In addition, the therapeutic procedure was painless and safe, without any adverse events. Therefore, MBSD is a promising topical PDT agent for biocompatible, safe, and effective acne treatment.

Keywords: Acne vulgaris; Methylene blue; Nanoformulation; Photodynamic therapy; Salicylic acid.

MeSH terms

  • Acne Vulgaris* / pathology
  • Aminolevulinic Acid
  • Anti-Infective Agents* / therapeutic use
  • Humans
  • Methylene Blue / therapeutic use
  • Photochemotherapy* / methods
  • Photosensitizing Agents
  • Propionibacterium acnes
  • Treatment Outcome

Substances

  • Methylene Blue
  • Photosensitizing Agents
  • Aminolevulinic Acid
  • Anti-Infective Agents